Glancy Prongay & Murray LLP is investigating potential claims against the Board of Directors of Muscle Pharm Corp. (“Muscle Pharm” or the “Company”) (OTC:MSLP). This investigation concerns the Company’s May 8, 2015 amendments to its By-laws and whether the Board of Directors of Muscle Pharm breached their fiduciary duties to stockholders by approving amendments which may place undue burden on stockholders’ ability to nominate and elect competing directors to the incumbent slate.

If you are a stockholder of Muscle Pharm, if you have information or would like to learn more about our investigation, or if you wish to discuss your rights or interests with respect to these matters, please contact Louis Boyarsky, Esquire, Glancy Prongay & Murray LLP, 1925 Century Park East, Suite 2100, Los Angeles, CA 90067, by telephone at (310) 201-9150 or Toll Free at (888) 773-9224 or by email to shareholders@glancylaw.com. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.


Contacts

Glancy Prongay & Murray LLP
Louis Boyarsky, Esquire
310-201-9150 or 888-773-9224
shareholders@glancylaw.com